Clinical Trial Update: Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma [Phase 2]

View source ↗

Summary

A completed Phase II open-label, non-randomized study evaluating the combination of sorafenib and everolimus in relapsed or non-resectable osteosarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Everolimus (everolimus)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Italian Sarcoma Group | Conditions: Metastatic Osteosarcoma, Relapsed Osteosarcoma | Phase 2 | Status: COMPLETED